Creative Medical Technology Holdings Advances Heart Disease Treatment
Creative Medical Technology Holdings Announces Notice of Allowance
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is excited to share that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its groundbreaking patent application titled, "Treatment Of Heart Failure And/Or Post Infarct Pathological Remodeling By Ex Vivo Reprogrammed Immune Cells." This news marks a significant milestone in the company's journey as a clinical-stage biotechnology firm focused on regenerative medicine.
Implications of the Patent Allowance
If granted, this patent will be effective until at least 2040, indicating a long timeframe for the company to leverage its proprietary technology. The patent showcases broad claims to treat individuals who are at risk of heart failure or are currently affected by it, utilizing the innovative ImmCelz product. This initiative addresses a pressing need, as over five million people in the United States experience heart failure, along with several million who suffer from chronic chest pain.
The ImmCelz Product
The ImmCelz product stands out as a minimally invasive solution, offered through an outpatient procedure. The technology incorporates a patient's own non-modified immune cells, cultivated with cell-free factors outside their body to enhance their regenerative capabilities before being reinjected. This approach presents a promising pathway to treat not only heart-related ailments but potentially a broader array of conditions.
CEO's Positive Outlook
Timothy Warbington, the CEO of Creative Medical Technology, expressed the significance of this Notice of Allowance, stating, "This strengthens our intellectual property portfolio and highlights the potential of our cell-based technology to forge new therapies that promote healing and repair in the body." He emphasized that the patent adds considerable value to their franchise, ensuring the continued development of their regenerative medicine platform.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is at the forefront of biotechnology, pioneering inventive solutions in regenerative medicine across various fields, including neurology and urology. The commitment to revamping patient care through cutting-edge cell therapies positions the company as a leader in its sector. As a result, they aim to improve outcomes for numerous patients facing challenging health issues.
Frequently Asked Questions
What is the Notice of Allowance regarding ImmCelz?
The Notice of Allowance indicates that Creative Medical Technology Holdings is close to securing a patent for its regenerative medicine technology aimed at treating heart failure.
How does the ImmCelz product work?
ImmCelz utilizes a patient’s immune cells, which are enhanced outside the body and then reinjected, providing them with regenerative properties to treat various conditions.
What is the target patient population for ImmCelz?
The ImmCelz product aims to benefit over five million individuals in the U.S. with heart failure and millions more with chronic chest pain.
Who is at the helm of Creative Medical Technology?
Timothy Warbington serves as the CEO, promoting innovative therapies and advancing the company's vision.
Where can I find more information about Creative Medical Technology Holdings?
For more details, you can contact them through their investor relations email or visit their official website.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
